Immunovia AB

IMMNOV

SE0006091997

Advanced Medical Equipment & Technology

Delayed Nasdaq Stockholm Other stock markets 06:36:55 2024-04-25 am EDT			5-day change	1st Jan Change
2.13 ^SEK	+1.43%		+19.41%	+20.49%

Apr. 22	Immunovia AB Announces Positive Results from the Model-Development Study for Its Next-Generation Pancreatic Cancer Detection Test	CI
Apr. 09	Immunovia, Proteomedix Create Assays for Pancreatic Cancer Detection Test	MT

This article is reserved for members

Already a member?

Not a member ?

Free registration

Latest news about Immunovia AB

Immunovia AB Announces Positive Results from the Model-Development Study for Its Next-Generation Pancreatic Cancer Detection Test	Apr. 22	CI
Immunovia, Proteomedix Create Assays for Pancreatic Cancer Detection Test	Apr. 09	MT
Immunovia Successfully Develops Assays to Measure Targeted Proteomedix for Its Next-Generation Pancreatic Cancer Test - Moving Forward Towards Model-Development Study	Apr. 09	CI
Transcript : Immunovia AB, 2023 Earnings Call, Feb 21, 2024	Feb. 21
Immunovia AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 21	CI
Immunovia AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 21	CI
Immunovia AB Elects Melissa Farina and Valerie Bogdan-Powers as New Board Members	Nov. 21	CI
Transcript : Immunovia AB, Q3 2023 Earnings Call, Nov 09, 2023	Nov. 09
Immunovia AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Immunovia Shares Surge on Discovery Study for New Pancreatic Cancer Test	Nov. 07	MT
Immunovia Successfully Completes Discovery Phase of Next-Generation Test Development	Nov. 07	CI
Immunovia AB Announces Board Appointments	23-10-03	CI
Transcript : Immunovia AB, H1 2023 Earnings Call, Aug 30, 2023	23-08-30
Immunovia AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-30	CI
Transcript : Immunovia AB - Special Call	23-07-12
Sweden's Immunovia Redirects Resources Towards Development of New Pancreatic Cancer Detection Test	23-07-12	MT
Immunovia to Significantly Restructure to Focus Resources on its Next-Generation Blood Test for Pancreatic Cancer Detection	23-07-11	CI
Immunovia AB Announces Board Changes	23-05-26	CI
Transcript : Immunovia AB, Q1 2023 Earnings Call, May 23, 2023	23-05-23
Immunovia AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-23	CI
Immunovia AB Announces Board Changes	23-05-22	CI
Philipp Von Hugo Resigns from Immunovia's Board at His Own Request	23-05-06	CI
Transcript : Immunovia AB - Special Call	23-05-03
Immunovia Names US Head as New Global CEO	23-05-02	MT
Immunovia AB Appoints New CEO	23-04-29	CI

Immunovia AB (publ) is a Sweden-based diagnostic company that is developing and commercializing blood tests for the early detection of cancer and autoimmune diseases based on Immunoviaâs test platform called IMMray. Tests are based on antibody biomarker microarray analysis using machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a disease biomarker signature. Immunovia Dx Laboratories locations in USA and Sweden provides laboratory testing services in two accredited reference laboratories.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-04-29 - Q1 2024 Earnings Release

More about the company

	1st Jan change	Capi.
IMMUNOVIA AB	+20.49%	8.73M
SARTORIUS AG	-14.08%	19.18B
QUIDELORTHO CORPORATION	-44.61%	2.73B
INNER MONGOLIA FURUI MEDICAL SCIENCE CO., LTD.	+16.10%	1.84B
SHANGHAI MICROPORT EP MEDTECH CO., LTD.	-3.24%	1.61B
BIOTAGE AB	+21.24%	1.18B
CONTEC MEDICAL SYSTEMS CO.,LTD	-21.52%	898M
REVENIO GROUP OYJ	-13.25%	710M
VAREX IMAGING CORPORATION	-16.68%	694M
CELLAVISION AB	+7.78%	526M